BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Oppenheimer

Oppenheimer started coverage on shares of BridgeBio Pharma (NASDAQ:BBIO) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage issued a market perform rating on the stock.

A number of other equities research analysts also recently weighed in on BBIO. Evercore ISI reduced their price target on shares of BridgeBio Pharma from $50.00 to $45.00 and set an outperform rating on the stock in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Pharma from $46.00 to $43.00 and set an overweight rating on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an overweight rating and issued a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, September 16th. HC Wainwright reiterated a buy rating and set a $43.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 30th. Finally, Piper Sandler began coverage on shares of BridgeBio Pharma in a research report on Wednesday, September 4th. They set an overweight rating and a $46.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of Moderate Buy and a consensus target price of $47.92.

BridgeBio Pharma Stock Down 1.6 %

BBIO stock opened at $25.23 on Thursday. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $44.32. The firm has a market cap of $4.72 billion, a P/E ratio of -7.84 and a beta of 1.08. The company’s 50-day moving average price is $26.08 and its two-hundred day moving average price is $26.92.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.96 million. During the same quarter in the previous year, the business posted ($0.98) earnings per share. The company’s revenue for the quarter was up 32.1% on a year-over-year basis. Equities analysts predict that BridgeBio Pharma will post -2.54 EPS for the current year.

Insider Transactions at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,155 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the transaction, the chief financial officer now owns 85,192 shares in the company, valued at approximately $2,103,390.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Brian C. Stephenson sold 4,155 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the transaction, the chief financial officer now owns 85,192 shares in the company, valued at approximately $2,103,390.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the completion of the transaction, the chief executive officer now owns 4,897,443 shares in the company, valued at $120,917,867.67. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,831,544 shares of company stock worth $150,128,821. Company insiders own 24.66% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bfsg LLC increased its stake in shares of BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. YHB Investment Advisors Inc. bought a new stake in shares of BridgeBio Pharma in the 1st quarter valued at $34,000. Headlands Technologies LLC bought a new stake in shares of BridgeBio Pharma in the 2nd quarter valued at $48,000. Quarry LP bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $50,000. Finally, EntryPoint Capital LLC bought a new stake in shares of BridgeBio Pharma in the 1st quarter valued at $117,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.